Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,836 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psychosis Clear all
Completed Phase 3 Interventional

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

NCT01192867
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO4917838, Antipshychotics (Standard of Care)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 19, 2026, 6:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Brain Stimulation to the Hippocampus in Schizophrenia

NCT07010614
View directory record Official record
Conditions
Schizophrenia Disorders, Mental Disorder, Psychotic Disorder
Interventions
Intracranial electrodes, TMS, TMS sham
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

NCT02104752
View directory record Official record
Conditions
Schizophrenia, Cognition, Psychosis
Interventions
Curcumin, Placebo
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 19, 2026, 6:43 AM EDT
Active, not recruiting Not applicable Interventional

Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

NCT04338152
View directory record Official record
Conditions
Psychotic Disorders, Prodromal Symptoms, Prodromal Schizophrenia, Psychosis, Family
Interventions
Family Focused Therapy for Clinical High Risk Youth (FFT-CHR), Enhanced Care (EC)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 25 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Phase 4 Interventional

Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)

NCT00453609
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Alcohol Dependence
Interventions
long-lasting injectable naltrexone
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2008 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Phase 2 Interventional

Glycine to Treat Psychotic Disorders in Children

NCT00005658
View directory record Official record
Conditions
Psychotic Disorder, Schizoaffecitve Disorder, Schizophrenia
Interventions
Glycine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 6:43 AM EDT
Completed No phase listed Observational

Effect of Antipsychotics on Appetite Regulation

NCT00903916
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Not applicable Interventional

Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia

NCT03287778
View directory record Official record
Conditions
Tardive Dyskinesia, Antipsychotic Agents
Interventions
Pyridoxine, Placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 19, 2026, 6:43 AM EDT
Recruiting Not applicable Interventional

Enhanced Coordinated Specialty Care for Early Psychosis

NCT06071858
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder, Psychosis Nos/Other, Bipolar Disorder
Interventions
Care Coordination, Individual Peer Support, Digital Outreach, Cognitive Remediation, Multi-Family Group Therapy
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
Not listed
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Belmont, Massachusetts • Boston, Massachusetts • Cambridge, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Phase 1 Interventional

Benefits Management for People With Psychiatric Disabilities

NCT01329393
View directory record Official record
Conditions
Dual Diagnosis, Schizophrenia, Bipolar Disorder
Interventions
Benefits Management, Illness Management and Recovery
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability Study of Drug to Treat Schizophrenia

NCT00044005
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 20 mg, Lurasidone 40 mg, Lurasidone 80mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
26
States / cities
Birmingham, Alabama • Cerritos, California • Garden Grove, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 19, 2026, 6:43 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

NCT01598896
View directory record Official record
Conditions
Cannabis Dependence, Marijuana Dependence
Interventions
Dronabinol, Clonidine, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

NCT05463770
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Network-Targeted Neuromodulation for Nicotine Dependence in Schizophrenia

NCT06389266
View directory record Official record
Conditions
Schizophrenia, Nicotine Dependence
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study

NCT02642029
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I
Interventions
Excitatory TMS, Inhibitory TMS, Sham TMS
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Belmont, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)

NCT00053703
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Olanzapine (enrollment closed in this treatment), Molindone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
8 Years to 19 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

NCT00176423
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
galantamine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 19, 2026, 6:43 AM EDT
Terminated Phase 4 Interventional Results available

Antipsychotic Effects on Brain Function in Schizophrenia

NCT01913327
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Aripiprazole, Risperidone, Modafinil
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Plasma Osmolality on Brain Glutamate

NCT00611741
View directory record Official record
Conditions
Schizophrenia
Interventions
furosemide, Na supplements
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 19, 2026, 6:43 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia

NCT07788755
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Cognitive Impairment, Visual Impairment
Interventions
Perceptual Discrimination Training, Cognitive Control Training
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 79 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

NCT00423878
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone, Olanzapine, Quetiapine, Aripiprazole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 19, 2026, 6:43 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

NCT02873208
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 3831
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 19, 2026, 6:43 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia

NCT07344948
View directory record Official record
Conditions
Healthy Participants, Schizophrenia Diagnosis
Interventions
NTX-253, Placebo
Drug
Lead sponsor
Neurosterix
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 19, 2026, 6:43 AM EDT
Terminated Phase 4 Interventional Results available

Fluoxetine vs Aripiprazole Comparative Trial (FACT)

NCT02357849
View directory record Official record
Conditions
Attenuated Psychosis Syndrome
Interventions
Aripiprazole, Fluoxetine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
12 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 19, 2026, 6:43 AM EDT